Table 2.

Indications of currently available TKI in advanced phase of chronic myeloid leukemia.

TKI	Relative potency against BCR-ABL1	Other targets	Indications in AP	Indications in BP
Imatinib	1 (reference)	PDGFR > c-KIT	AP-CML or BP-CML
Nilotinib	≈25	PDGFR	AP-CML with resistance of intolerance to prior therapy including imatinib	Not indicated
Dasatinib	≈325	Src > BTK > PDGFR > c-KIT	AP-CML or BP-CML with resistance of intolerance to prior therapy including imatinib
Bosutinib	≈15	BTK > Src	AP-CML or BP-CML previously treated with one or more TKI (s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options (EMA) AP-CML or BP-CML with resistance or intolerance to prior therapy (FDA)
Ponatinib	≈900	PDGFR > VEGFR2 > Src > c-KIT	AP-CML or BP-CML who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation (EMA) AP-CML or BP-CML resistant or intolerant to prior TKI therapy (FDA)

AP, accelerated phase; BP, blast phase; PDGFR, Platelet-derived Growth Factor Receptor; BTK, Bruton's Tyrosine Kinase; TKI, Tyrosine Kinase Inhibitors; EMA, European Medicine Agency; FDA, Food and Drug Administration.